Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2015

Open Access 01-12-2015 | Research

Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study

Authors: Kumiko Hongo, Shinsuke Kazama, Nelson H Tsuno, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe

Published in: World Journal of Surgical Oncology | Issue 1/2015

Login to get access

Abstract

Background

High-mobility group box 1 (HMGB1) is a nucleoprotein that is related to inflammation. It has been implicated in a variety of biologically important processes, including transcription, DNA repair, differentiation, development, and extracellular signaling. Recently, its important role in the process of tumor invasion, metastasis, and resistance to anti-cancer therapies has been demonstrated. In this study, we aimed to investigate the correlation of HMGB1 expression and resistance of rectal cancer patients to chemoradiotherapy (CRT) prior to curative operation.

Methods

We retrospectively reviewed the data of 75 lower rectal cancer patients without complete pathological response who had received preoperative CRT and had undergone curative resection at the University of Tokyo Hospital between May 2003 and June 2010. HMGB1 expression in surgically resected specimens was evaluated using immunohistochemical detection and specimens were classified into high or low HMGB1 expression groups. Clinicopathologic features, degree of tumor reduction, regression of tumor grade, and patient survival were compared between the groups using non-paired Student’s t-tests and Kaplan-Meier analysis.

Results

A total of 52 (69.3%) patients had high HMGB1 expression, and 23 (30.7%) had low expression. HMGB1 expression was significantly correlated with histologic type (P = 0.02), lymphatic invasion (P = 0.02), and venous invasion (P = 0.05). Compared to patients with low HMGB1 expression, those with high expression had a poorer response to CRT, in terms of tumor reduction ratio (42.2 versus 28.9%, respectively; P <0.01) and post-CRT histological tumor regression grade (56.5 versus 30.8% grade 2; respectively; P = 0.03). However, no significant correlation was found between HMGB1 expression and recurrence-free and overall survival rates.

Conclusions

HMGB1 expression may be one of the key factors regulating the response of rectal cancer to preoperative CRT in terms of tumor invasiveness and resistance to therapy.
Literature
1.
Czura CJ, Wang H, Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001, 7:315–21.CrossRefPubMed
2.
Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331–42. 10.1038/nri1594CrossRefPubMed
3.
Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al.: New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001, 20:4337–40. 10.1093/emboj/20.16.4337CrossRefPubMedCentralPubMed
4.
Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, et al.: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007, 30:596–606. 10.1097/CJI.0b013e31804efc76CrossRefPubMed
5.
Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al.: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007, 13:2836–48. 10.1158/1078-0432.CCR-06-1953CrossRefPubMed
6.
7.
Erlandsson Harris H, Andersson U: Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004, 34:1503–12. 10.1002/eji.200424916CrossRefPubMed
8.
Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191–5. 10.1038/nature00858CrossRefPubMed
9.
Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al.: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652–60. 10.1182/blood-2002-05-1300CrossRefPubMed
10.
Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004, 101:296–301. 10.1073/pnas.2434651100CrossRefPubMedCentralPubMed
11.
Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al.: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006, 290:C917–24.CrossRefPubMed
12.
Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al.: HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004, 5:825–30. 10.1038/sj.embor.7400205CrossRefPubMedCentralPubMed
13.
Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004, 255:320–31. 10.1111/j.1365-2796.2003.01302.xCrossRefPubMed
14.
Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al.: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. Journal Exp Med 2005, 201:1135–43. 10.1084/jem.20042614CrossRef
15.
Tang D, Kang R, Cao L, Zhang G, Yu Y, Xiao W, et al.: A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med 2008, 36:291–5. 10.1097/01.CCM.0000295316.86942.CECrossRefPubMed
16.
Qi ML, Tagawa K, Enokido Y, Yoshimura N, Wada Y, Watase K, et al.: Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol 2007, 9:402–14. 10.1038/ncb1553CrossRefPubMed
17.
Enokido Y, Yoshitake A, Ito H, Okazawa H: Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain. Biochem Biophys Res Commun 2008, 376:128–33. 10.1016/j.bbrc.2008.08.108CrossRefPubMed
18.
Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al.: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009, 7:17. 10.1186/1479-5876-7-17CrossRefPubMedCentralPubMed
19.
Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, et al.: Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004, 164:441–9. 10.1083/jcb.200304135CrossRefPubMedCentralPubMed
20.
Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248–51. 10.1126/science.285.5425.248CrossRefPubMed
21.
Yu W, Kim J, Ossowski L: Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997, 137:767–77. 10.1083/jcb.137.3.767CrossRefPubMedCentralPubMed
22.
Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354–60. 10.1038/35012626CrossRefPubMed
23.
Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005, 64:92–100. 10.1002/pros.20219CrossRefPubMed
24.
Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, et al.: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006, 55:234–42. 10.1136/gut.2004.062729CrossRefPubMedCentralPubMed
25.
Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, et al.: Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 2003, 63:2188–93.PubMed
26.
Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010, 136:677–84. 10.1007/s00432-009-0706-1CrossRefPubMed
27.
Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, et al.: HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 2010, 77:17–23. 10.1159/000272950CrossRefPubMed
28.
Yang H, Wang H, Czura CJ, Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol 2005, 78:1–8. 10.1189/jlb.1104648CrossRefPubMed
29.
Huttunen HJ, Fages C, Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999, 274:19919–24. 10.1074/jbc.274.28.19919CrossRefPubMed
30.
Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005, 26:293–301.CrossRefPubMed
31.
Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al.: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010, 29:5299–310. 10.1038/onc.2010.261CrossRefPubMedCentralPubMed
32.
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al.: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 2012, 72:230–8. 10.1158/0008-5472.CAN-11-2001CrossRefPubMed
33.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al.: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050–9. 10.1038/nm1622CrossRefPubMed
34.
Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al.: HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009, 6:e10. 10.1371/journal.pmed.1000010CrossRefPubMed
35.
Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW: Colorectal cancer. Lancet 2005, 365:153–65. 10.1016/S0140-6736(05)17706-XCrossRefPubMed
36.
Belluco C, De Paoli A, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A, et al.: Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol 2011, 18:3686–93. 10.1245/s10434-011-1822-0CrossRefPubMedCentralPubMed
37.
Sobin LH, Gospodarowicz MK, Wittekind C: TNM Classification of Malignant Tumors. .7th edition. Hoboken, NJ, United States: Wiley-Blackwell; 2009.
38.
Organnization WH: International Classification of Diseases for Oncology. 3rd edition. International Association of Cancer Registries: Lyon, France; 2000.
39.
Rectum JS, Cot C: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum, and Anus. Tokyo, Japan: Kanehara & Co; 2006.
40.
Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1–5.CrossRefPubMed
41.
42.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454:436–44. 10.1038/nature07205CrossRefPubMed
43.
Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004, 4:641–8. 10.1038/nri1415CrossRefPubMed
44.
Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, et al.: High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008, 99:1806–12.PubMed
45.
Yuan F, Gu L, Guo S, Wang C, Li GM: Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem 2004, 279:20935–40. 10.1074/jbc.M401931200CrossRefPubMed
46.
Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, et al.: High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011, 13:701–11. 10.1016/j.cmet.2011.04.008CrossRefPubMedCentralPubMed
47.
Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, et al.: HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011, 25:23–31. 10.1038/leu.2010.225CrossRefPubMed
48.
Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A: Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008, 68:1485–94. 10.1158/0008-5472.CAN-07-0562CrossRefPubMed
49.
Metadata
Title
Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study
Authors
Kumiko Hongo
Shinsuke Kazama
Nelson H Tsuno
Soichiro Ishihara
Eiji Sunami
Joji Kitayama
Toshiaki Watanabe
Publication date
01-12-2015
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2015
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-13-7

Other articles of this Issue 1/2015

World Journal of Surgical Oncology 1/2015 Go to the issue

Research

Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction

Research

Breast cancer survival experiences at a tertiary hospital in sub-Saharan Africa: a cohort study

Research

Predictors of early recurrence after resection of colorectal liver metastases

Research

Surgical management and outcome of rectal carcinoids in a university hospital

Review

Surveillance radiologic imaging after treatment of oropharyngeal cancer: a review

Case report

Laparoscopic radical right hemicolectomy for cecal cancer and middle colic artery aneurysm